AIM
CLB icon

Acrospire Investment Management’s Core Laboratories CLB Stock Holding History

Acrospire Investment Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200
Closed -$20K – 284
2017
Q2 		$20K Buy
+200
New +$21.6K 0.02% 1515

Other funds holding CLB

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Wedgewood Partners St Louis, Missouri $484M AUM 14.59% 1-Year Est. Return

Acrospire Investment Management's CLB Position: Q3 2017 in Review

Acrospire Investment Management sold out of Core Laboratories (CLB) in Q3 2017, closing a stake of 200 shares — an estimated $20K sold.

Acrospire Investment Management first reported a position in CLB in Q2 2017 and held it in 1 quarter. The position peaked at $20K in Q2 2017. 345 funds tracked by Wall St. Rank hold CLB as of Q3 2017.

  • Acrospire Investment Management reported no remaining Core Laboratories position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 200 Core Laboratories shares in Q3 2017, an estimated $20K.
  • Acrospire Investment Management first reported a position in Core Laboratories in Q2 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Core Laboratories position peaked at $20K in Q2 2017.
  • 345 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.